Sera Prognostics (NASDAQ:SERA) Shares Down 2.8% – Here’s Why

Sera Prognostics, Inc. (NASDAQ:SERA)’s stock price was down 2.8% during mid-day trading on Thursday . The stock traded as low as $2.78 and last traded at $2.80. Approximately 24,971 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 54,412 shares. The stock had previously closed at $2.88.

Analyst Ratings Changes

Several equities analysts have recently weighed in on SERA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a research report on Monday, December 29th. Jefferies Financial Group raised shares of Sera Prognostics to a “strong-buy” rating in a research note on Monday, December 15th. Finally, Wall Street Zen raised shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Sera Prognostics Stock Down 2.8%

The firm has a market cap of $108.08 million, a PE ratio of -3.64 and a beta of 0.99. The business has a 50 day simple moving average of $3.32 and a two-hundred day simple moving average of $3.11.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Sera Prognostics had a negative net margin of 34,343.16% and a negative return on equity of 41.69%. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.10 million. Equities analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Insider Activity at Sera Prognostics

In other news, CEO Zhenya Lindgardt sold 28,215 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $3.04, for a total transaction of $85,773.60. Following the transaction, the chief executive officer directly owned 768,081 shares of the company’s stock, valued at approximately $2,334,966.24. This trade represents a 3.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 52,587 shares of company stock worth $163,108 over the last 90 days. Company insiders own 13.50% of the company’s stock.

Hedge Funds Weigh In On Sera Prognostics

A number of hedge funds and other institutional investors have recently made changes to their positions in SERA. Wealth Enhancement Advisory Services LLC bought a new position in shares of Sera Prognostics during the fourth quarter valued at approximately $31,000. Lido Advisors LLC acquired a new position in Sera Prognostics during the 3rd quarter valued at about $68,000. Citadel Advisors LLC raised its position in shares of Sera Prognostics by 1.9% in the 3rd quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock valued at $2,000,000 after purchasing an additional 12,439 shares during the last quarter. Two Sigma Investments LP purchased a new position in shares of Sera Prognostics in the third quarter worth $97,000. Finally, Squarepoint Ops LLC raised its stake in Sera Prognostics by 8.9% in the 3rd quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock worth $285,000 after acquiring an additional 7,643 shares during the last quarter. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.